Close Menu

NEW YORK – Precision oncology company Novellus said on Wednesday that it has entered into an exclusive worldwide license agreement with Plexxikon for its BRAF inhibitor PLX8394.

PLX8394 is an investigational drug that is currently being studied in Phase I/II trials in BRAF-mutated tumors. 

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.